Respiratory Medicine


Cystic Fibrosis (CF) is a genetic condition resulting in mainly respiratory and gastrointestinal problems, and is associated with early death from lung damage and respiratory failure. CF is more common in Ireland than anywhere else. Our CF research team led by Professor Paul McNally is passionate about putting Ireland at the forefront of paediatric CF research internationally. Our CF research programme has three main strands – we believe that developing and integrating these strands will drive significant improvements in the care and outcomes for our patients with CF.

  1.  High quality basic science CF research.
    Our basic Science team led by Dr Judith Coppinger has a particular interest in biomarkers of lung disease.
  2.  High quality clinical and translational research.
    Our main study in this area is SHIELD CF – a long term comprehensive multi-centre study designed to help us to understand the origins of CF lung disease in babies and small children by collecting and banking clinical information and samples over many years.
  3.  A network for clinical trials.
    Our CF:INK network covers all of the specialist paediatric CF centres in Ireland and was developed to bring clinical trials of new medications to all children with CF in Ireland.

Our philosophy is based around establishing a comprehensive national network for high quality CF research, with NCRC at the centre. We want to create strong links between patient care and research to drive improvements in outcomes for children with this debilitating disease.

Current Trials & Studies

Study NameStudy TitleStudy TypeSponsorSponsor Type
SHIELD CFThe Study of Host Immunity and Early Lung Disease in Children with CFNon-Interventional StudyNCRCAcademic - Investigator Led
VX14-661-110A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR MutationClinical TrialVertexIndustry Sponsored
VOICE: VX14-CFR-107Observational Registry of Cystic Fibrosis Patients in EuropeNon-interventional studyVertexIndustry Sponsored
CUBS (CF Urinary biomarker study)CF Urinary biomarker studyNon-interventional studyNCRCAcademic - Investigator Led
PALM StudyPALM study (Protease activity: Lung measurement) – a longitudinal study in children with CF to establish spectrum and influence of protease antiprotease activity in CF Starting in JulyNon-Interventional StudyNCRCAcademic - Investigator Led
VX15-770-124A Phase 3, 2-Part, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating MutationClinical TrialVertexIndustry Sponsored
VX15-770-126A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation.Clinical TrialVertexIndustry Sponsored

Past Trials & Studies

Study NameStudy TitleStudy TypeSponsorSponsor Type
VX15-371-101A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With OrkambiClinical TrialVertexIndustry Sponsored
VX14-661-106A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With IvacaftorClinical TrialVertexIndustry Sponsored
VX14-661-109A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR MutationClinical TrialVertexIndustry Sponsored
VX12-809-103A Phase 3, Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 years and older with Cystic Fibrosis, Homozygous for the F508del CFTR Mutation (TRAFFIC)Clinical TrialVertexIndustry Sponsored
VX12-809-105A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR MutationClinical TrialVertexIndustry Sponsored
MPEX-209A Phase 3, Open-label, Randomised Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation solution (Aeroquin) versus Tobramycin Inhalation Solution in stable Cystic Fibrosis patientsClinical TrialMpex Pharmaceuticals Inc.Industry Sponsored
VX08-770-103A Phase 3, 2-Part, Randomised, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 -11 years with Cystic Fibrosis and G551D mutationClinical TrialVertexIndustry Sponsored
VX08-770-105An Open Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic FibrosisClinical TrialVertexIndustry Sponsored
TR02-108Randomised, Open Label, Active controlled, multicentre study to assess the efficacy, safety and tolerability of ArikaceTM in Cystic Fibrosis Patients with Chronic Infection due to Pseudomonas AeruginosaClinical TrialInsmed IncIndustry Sponsored
TR02-110Long term safety and tolerability study of open-label liposomal amikacin for inhalation (Arikace) in Cystic Fibrosis patients with chronic infection due to Pseudomonas AeruginosaClinical TrialInsmed IncIndustry Sponsored
PsAer-IgYProspective randomised, placebo controlled, double-blind, multicentre study (Phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patientsClinical TrialMukoviszidosAcademic - Collaborative Group
Caregiver Burden StudyCaregiver Burden Study in Cystic Fibrosis in the United States, Germany, United Kingdom and IrelandNon-Interventional StudyVertexIndustry Sponsored
The POOL studyInflammatory and Microbiological Implications of Pooling of Bronchoalveolar Lavage samples in Preschool Children with Cystic FibrosisNon-Interventional StudyNCRCAcademic - Investigator Led
Rhinovirus pilot studyThe Role of Human Rhinovirus Infections in Young Children with Cystic Fibrosis - A Pilot StudyNon-Interventional StudyNCRCAcademic - Investigator Led